戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 and a microRNA biomarker/mechanism for toxic epidermal necrolysis.
2 hylaxis, Stevens-Johnson syndrome, and toxic epidermal necrolysis.
3 disease, Stevens-Johnson syndrome, and toxic epidermal necrolysis.
4 ents with Stevens-Johnson syndrome and toxic epidermal necrolysis.
5 ermatoses Stevens-Johnson syndrome and toxic epidermal necrolysis.
6 rogressing Stevens-Johnson syndrome or toxic epidermal necrolysis.
7 ide mediates the epidermal necrosis in toxic epidermal necrolysis and provides a potential target for
8                                        Toxic epidermal necrolysis and Stevens-Johnson syndrome are se
9  that a large burst of nitric oxide in toxic epidermal necrolysis and Stevens-Johnson syndrome may ca
10 ay rarely progress to life-threatening toxic epidermal necrolysis, and colitis, characterized by a mi
11 licated in the pathogenesis of eczema, toxic epidermal necrolysis, and drug-induced skin eruptions.
12 s (resulting from pneumococcal sepsis, toxic epidermal necrolysis, and renal failure) occurred at dos
13           Stevens-Johnson syndrome and toxic epidermal necrolysis are severe adverse cutaneous drug r
14 syndrome, and Stevens-Johnson syndrome/toxic epidermal necrolysis, can be severe and result in a dive
15  admitted for Stevens-Johnson syndrome/toxic epidermal necrolysis over a 14-year period were included
16 n one of four Stevens-Johnson syndrome/toxic epidermal necrolysis patients and is associated with a p
17 tification of Stevens-Johnson syndrome/toxic epidermal necrolysis patients at higher risk of intubati
18                  A teenage survivor of toxic epidermal necrolysis presented with faint but diffuse dy
19 ugh rare, Stevens-Johnson syndrome and toxic epidermal necrolysis remain among the most devastating o
20 hod and the Algorithm for Drug Causality for Epidermal Necrolysis, respectively.
21           Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare but severe adver
22 volved in Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), although a detailed desc
23 and Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) among carbamazepine users, es
24                                        Toxic epidermal necrolysis (TEN) and Stevens-Johnson Syndrome
25     Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening disorder
26     Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening
27     Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening
28 induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) as a model to study the patho
29                                        Toxic epidermal necrolysis (TEN) is a severe adverse drug reac
30        Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and graft-versus-host diseas
31 luding Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia
32 uch as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug rash with eosinophil
33 ons Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
34 hod and the Algorithm for Drug Causality for Epidermal Necrolysis was highly probable or probable in
35 e child in the placebo group had fatal toxic epidermal necrolysis with concurrent Pseudomonas aerugin

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。